There are ongoing clinical trials to examine the benefit of myosin inhibitors in non-obstructive HCM with data likely expected in early 2025.40 There are also efforts to determine whether the success of sodium-glucose cotransporter-2 inhibitors seen in heart failure with preserved ejection fraction may also be of benefit in non-obstructive HCM.41 The gene discussed is SLC5A2; the disease is heart failure.